• ISSN 16748301
  • CN 32-1810/R
Volume 32 Issue 4
Apr.  2018
Article Contents

Citation:

Clinical features of multiple myeloma patients with isolated extramedullary relapse

  • Received Date: 2014-07-09
    Accepted Date: 2014-10-16

    Fund Project: This work was supported by Foundation of National Natural Science Foundation of China (81241074,81071946 and 81302040), Natural Science Foundation of Jiangsu Province (BK2012485), Jiangsu Province's Medical Elite Program (RC201148) a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions, the Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU, Clinical Research Program from Health Ministry of China (Key project 2010 to 2012), and Scientific Research Program for Public Interests from the Health Ministry of China (No. 201202017)

  • This study sought to analyze the clinical features and prognosis of multiple myeloma with isolated extramedullary relapse and with the absence of systemic progression. The clinical features and outcome were retrospectively analyzed in six multiple myeloma patients. These patients had secretory multiple myeloma at diagnosis. When relapsed, the dissociation between medullary and extramedullary response was detected. The serum or urine monoclonal component was extremely low or absent. The plasma cells in bone marrow were < 5%. All patients received new targeted therapies (thalidomide or bortezomib) before extramedullary relapse. It is difficult to achieve second remission for them. Even in those showing response, the duration of response was extremely short. The median of overall survival from diagnosis and from extramedullary relapse was 19 months and 6 months, respectively. The overall survival was significantly shorter compared to the patients without extramedullary involvement (84 months, P = 0.001). These patients exhibited a special and rare relapse pattern. Patients with this relapse pattern were resistant to current therapies, including novel targeted agents and associated with poor prognosis.
  • 加载中
  • 加载中

Article Metrics

Article views(205) PDF downloads(77) Cited by()

Related
Proportional views
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Clinical features of multiple myeloma patients with isolated extramedullary relapse

  • 1. Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China.
Fund Project:  This work was supported by Foundation of National Natural Science Foundation of China (81241074,81071946 and 81302040), Natural Science Foundation of Jiangsu Province (BK2012485), Jiangsu Province's Medical Elite Program (RC201148) a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions, the Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU, Clinical Research Program from Health Ministry of China (Key project 2010 to 2012), and Scientific Research Program for Public Interests from the Health Ministry of China (No. 201202017)

Abstract: This study sought to analyze the clinical features and prognosis of multiple myeloma with isolated extramedullary relapse and with the absence of systemic progression. The clinical features and outcome were retrospectively analyzed in six multiple myeloma patients. These patients had secretory multiple myeloma at diagnosis. When relapsed, the dissociation between medullary and extramedullary response was detected. The serum or urine monoclonal component was extremely low or absent. The plasma cells in bone marrow were < 5%. All patients received new targeted therapies (thalidomide or bortezomib) before extramedullary relapse. It is difficult to achieve second remission for them. Even in those showing response, the duration of response was extremely short. The median of overall survival from diagnosis and from extramedullary relapse was 19 months and 6 months, respectively. The overall survival was significantly shorter compared to the patients without extramedullary involvement (84 months, P = 0.001). These patients exhibited a special and rare relapse pattern. Patients with this relapse pattern were resistant to current therapies, including novel targeted agents and associated with poor prognosis.

    HTML

Catalog

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return